Browse > Article
http://dx.doi.org/10.5012/jkcs.2013.57.6.744

Designing Hypothesis of 2-Substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl] Acetamide Analogs as Anticancer Agents: QSAR Approach  

Bedadurge, Ajay B. (Bhujbal Knowledge City, MET's Institute of Pharmacy)
Shaikh, Anwar R. (Bhujbal Knowledge City, MET's Institute of Pharmacy)
Publication Information
Abstract
Quantitative structure-activity relationship (QSAR) analysis for recently synthesized imidazole-(benz)azole and imidazole - piperazine derivatives was studied for their anticancer activities against breast (MCF-7) cell lines. The statistically significant 2D-QSAR models ($r^2=0.8901$; $q^2=0.8130$; F test = 36.4635; $r^2$ se = 0.1696; $q^2$ se = 0.12212; pred_$r^2=0.4229$; pred_$r^2$ se = 0.4606 and $r^2=0.8763$; $q^2=0.7617$; F test = 31.8737; $r^2$ se = 0.1951; $q^2$ se = 0.2708; pred_$r^2=0.4386$; pred_$r^2$ se = 0.3950) were developed using molecular design suite (VLifeMDS 4.2). The study was performed with 18 compounds (data set) using random selection and manual selection methods used for the division of the data set into training and test set. Multiple linear regression (MLR) methodology with stepwise (SW) forward-backward variable selection method was used for building the QSAR models. The results of the 2D-QSAR models were further compared with 3D-QSAR models generated by kNN-MFA, (k-Nearest Neighbor Molecular Field Analysis) investigating the substitutional requirements for the favorable anticancer activity. The results derived may be useful in further designing novel imidazole-(benz)azole and imidazole-piperazine derivatives against breast (MCF-7) cell lines prior to synthesis.
Keywords
Imidazole-(benz)azole and imidazole-piperazine; Breast (MCF-7) cell line; Anticancer; Quantitative structure-activity relationship; kNN-MFA;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Krikas, G.; Schulpis, K.; Reclos, G.; Kokotos, G. Clin. Biochem. 1998, 31, 405.   DOI   ScienceOn
2 Waring, M.; Bailly, C. Gene 1994, 149, 69.   DOI   ScienceOn
3 Rehn, C.; Pindur, U. Monatsh. Chem. 1996, 127, 631.   DOI
4 Baginski, M.; Fogolari, F.; Briggs, J. J. Mol. Biol. 1997, 274, 253.   DOI   ScienceOn
5 Shui, X.; et al. Curr. Med. Chem. 2000, 7, 59.   DOI
6 Neidle, S. In Cancer Drug Desing and Discovery, 2nd Ed.; Elsevier Inc.: U.S.A., 2008, p 132.
7 Moore, M.; Hunter, W.; Langlis-D'Estaintot, B.; Kennard, O. J. Mol. Bio. 1989, 206, 693.   DOI
8 Pindur, U.; Haber, M.; Sattler, K. J. Chem. Educ. 1993, 70, 263.   DOI   ScienceOn
9 Zhigang, L.; Qing, Y.; Xuhong, Q. Bioorg. Med. Chem. Lett. 2005, 15, 3143.   DOI   ScienceOn
10 Claiborne, C.; Liverton, N.; Nguyen, K. Tetrahedron Lett. 1998, 39, 8939.   DOI   ScienceOn
11 Cui, B.; Zheng, B.; He, K.; Zheng, Q. J. Nat. Prod. 2003, 66, 1101.   DOI   ScienceOn
12 Fazeny-Dorner, B.; Veitl, M.; Wenzel, C.; Piribauer, M.; Rossler, K.; Dieckmann, K.; Ungersbock, K.; Marosi, C. Anticancer Drugs. 2003, 14, 437.   DOI   ScienceOn
13 Haluska, P.; Dy, G.; A. Adjei, A. Eur. J. cancer. 2008, 38, 1685.
14 Kotteas, E.; Alamara, C.; Kiagia, M.; Pantazopoulos, K.; Oufas, A.; Provata, A.; Chapidou, A.; Syrigos, K. N. Anticancer Res. 2008, 28, 529.
15 Perez-ruixo, J.; Piotrovskij, V.; Zhang, S.; Hayes, S.; DePorre, P.; Zannikos, P. Br. J. Clin, Pharmacol. 2006, 62, 81.   DOI   ScienceOn
16 Krezel, I. Farmaco 1998, 53, 342.   DOI   ScienceOn
17 Kumar, D.; Jacob, M. R.; Reynolds, M. B.; Kerwin, S. M. Bioorg. Med. Chem. 2002, 10, 3997.   DOI   ScienceOn
18 Hose, C.; Hollingshead M.; Sausville E.; Monks A.; Mol. Cancer Ther. 2003, 2, 1265.
19 Al-Masoudi, A.; Al-Soud, Y.; Al-Salihi, N.; Al-Masoudi, N. Chem. Hetetrocycl. Compd. 2006, 42, 1377.   DOI
20 Jackman, A.; Kimbell, R.; Aherne, G.; Brunton, L.; Jansen, G.; Stephens, T.; Smith, M.; Wardleworth, J.; Boyle, F. Clin. Cancer Res. 1997, 3, 911.
21 Nelson, J.; Rose, L.; Benneft, L. Cancer Res. 1977, 37, 182.
22 Martin, B.; Mann, J.; Sageot, A. J. Chem. Soc. Perkin Trans. 1, 1999, 2455.
23 Golbraikh, A.; Tropsha, A. J. Comput. Aided Mol. Des. 2002, 16, 357.   DOI   ScienceOn
24 Brian, B.; Andrew, M.; Hana, K.; Padmakumari, T.; William, P.; Jack, C. Mol. Pharmacol. 1997, 52, 839.   DOI
25 Hansch, C.; Kurup, A.; Garg, R.; Gao, H. Chem. Rev. 2001, 101, 619.   DOI   ScienceOn
26 Yusuf, O.; Ilhan, I.; Zerrin, I.; Gulsen, A. Eur. J. Med. Chem. 2010, 45, 3320.   DOI   ScienceOn
27 VLifeMDS 4.2; Molecular Design Suite; Vlife Sciences Technologies Pvt. Ltd.: Pune, India, 2012. www.vlifesciences.com
28 Gasteiger, J; Marsili, M. Tetrahedron. 1980, 36, 3219.   DOI   ScienceOn
29 Ajmani, S.; Jhadav, K.; Kulkarni, S. A. J. Chem. Inf. Model. 2006, 46, 24.   DOI   ScienceOn